Tankyrase inhibitors and β-catenin/CPB (cAMP response element-binding protein) antagonists acting in the cytoplasm and nucleus, respectively, have been previously proposed to suppress WNT signaling in APC-mutated CRC cells (Chen et al., 2009; Huang et al., 2009; Waaler et al. The gene discussed is APC; the disease is colorectal carcinoma.